Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of NYX-458 in Healthy Volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NYX-458 (Primary)
Indications Alzheimer's disease; Cognition disorders
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Aptinyx

Most Recent Events

30 Apr 2019 Results assessing the safety and pharmacokinetics is published in the Aptinyx Media Release
14 Aug 2018 According to an Aptinyx media release, trial completion expected in first half of 2019.
08 Aug 2018 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com